Skip to content

Monte Rosa Therapeutics, Inc. GLUE Finance Lease Liabilities

Finance Lease Liabilities at other companies

Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$1.15M-39.7%
Incyte logo
IncyteINCY
$29.41M-9.9%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$213K
Alumis Inc. logo
Alumis Inc.ALMS
$0

Other financials

Income statement

See full
Revenue$4.2M-95.0%
Operating income-$50.0M-214%
Net income-$44.5M-195%
EPS (diluted)-$0.45-179%

Balance sheet

See full
Cash & equivalents$159.9M+104%
Total debt$39.1M-6.7%
Total equity$521.9M+89.7%
Total assets$736.4M+87.3%

Cash flow

See full
Operating cash flow-$37.4M+17.9%
CapEx$1.9M+17.7%
Free cash flow-$39.2M+16.7%

Valuation

See full
Market cap$1.75B+361%
Enterprise value$1.63B+381%
P/S40.7×+38.4×

Profitability

See full
Operating margin-345.2%
Net margin-302.6%
FCF margin-45.8%-64.9pp

Returns & leverage

See full
Return on equity-32.6%
Debt / equity0.1×-0.1×
Current ratio9.5×+3.9×

Where this comes from

Reported directly by Monte Rosa Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiability.

The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monte Rosa Therapeutics, Inc.'s finance lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Monte Rosa Therapeutics, Inc.'s finance lease liabilities?
Monte Rosa Therapeutics, Inc. (GLUE) reported finance lease liabilities of $0 in Q1 2026.
What does finance lease liabilities mean?
Present value of future payments on leases classified as finance leases under ASC 842 — treated similarly to debt on the balance sheet.